NCT06680180 Fibrinolysis Resistance in Infection and Trauma
| NCT ID | NCT06680180 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anders Aneman |
| Condition | Sepsis and Septic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-06-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.
Eligibility Criteria
Sepsis/Septic shock Inclusion Criteria: * Admission to ICU, needing at least one organ supportand principally for the management of clinically suspected Sepsis or Septic shock according to Spesis-3 criteria (including SARS-COV-2) * Expected to remain in ICU and survive beyond the day after tomorrow Sepsis Exclusion Criteria: * On oral anticoagulant/antiplatelet therapy * Not for full, active ICU support * Death is deemed inevitable within 24 hrs Trauma Inclusion Criteria: * Trauma is the principal diagnosis on ICU admission * Expected to remain in ICU and survive beyond the day after tomorrow * Receiving respiratory support at the time of ICU admission - high-flow nasal prongs, non-invasive or invasive ventilation * Already received, or considered at risk of needing a blood product transfusion within 24 hrs of injury Trauma Exclusion Criteria: * Nursing home resident * Unsurvivable head injury * Not for full, active ICU support * Death is deemed inevitable within 24 hrs
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06680180 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis and Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06680180 currently recruiting?
Yes, NCT06680180 is actively recruiting participants. Contact the research team at anders.aneman@health.nsw.gov.au for enrollment information.
Where is the NCT06680180 trial being conducted?
This trial is being conducted at Canberra, Australia, Liverpool, Australia, Macquarie, Australia, St Leonards, Australia.
Who is sponsoring the NCT06680180 clinical trial?
NCT06680180 is sponsored by Anders Aneman. The trial plans to enroll 150 participants.